Allogene Therapeutics
Clinical trials sponsored by Allogene Therapeutics, explained in plain language.
-
New CAR t therapy aims to wipe out hidden lymphoma cells after first treatment
Disease control Recruiting nowThis study tests a new treatment called cemacabtagene ansegedleucel (cema-cel) for adults with large B-cell lymphoma who have tiny amounts of cancer left after their first round of therapy. About 250 participants will either receive cema-cel (a type of CAR T cell therapy made fro…
Phase: PHASE2 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated May 17, 2026 04:16 UTC
-
Engineered immune cells take on lupus, scleroderma, and myositis
Disease control Recruiting nowThis early-stage study tests a new treatment called ALLO-329 for people with lupus, myositis, or scleroderma. ALLO-329 uses specially engineered immune cells from a donor to target and calm overactive immune cells that cause these diseases. The main goal is to check safety and fi…
Phase: PHASE1 • Sponsor: Allogene Therapeutics • Aim: Disease control
Last updated May 14, 2026 12:04 UTC